Harmony Biosciences/$HRMY

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Harmony Biosciences

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

Ticker

$HRMY
Primary listing

Industry

Pharmaceuticals

Employees

268

ISIN

US4131971040

HRMY Metrics

BasicAdvanced
$1.8B
12.04
$2.62
0.82
-

What the Analysts think about HRMY

Analyst ratings (Buy, Hold, Sell) for Harmony Biosciences stock.

Bulls say / Bears say

Harmony Biosciences reported a 22.8% increase in revenue for 2024, reaching $714.73 million, indicating strong financial growth. (stockanalysis.com)
The company's flagship product, WAKIX, is not a controlled substance, making it more accessible and safer for patients compared to competitors. (finviz.com)
Analysts have a 'Strong Buy' consensus for HRMY, with a 12-month price forecast of $53.75, suggesting a potential upside of 56.61%. (stockanalysis.com)
Harmony Biosciences received a Refusal to File letter from the FDA for pitolisant in treating idiopathic hypersomnia, potentially delaying product expansion. (businesswire.com)
The company announced a public offering of up to 8 million shares by selling shareholders, which led to an 18% drop in stock price, indicating potential dilution concerns. (benzinga.com)
Harmony Biosciences is under investigation by Bronstein, Gewirtz & Grossman, LLC for potential claims, which could impact investor confidence. (accessnewswire.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Jun 2025.

HRMY Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

HRMY Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $HRMY

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs